Monopar Therapeutics — Director's Dealing 2023

Feb 4, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Monopar Therapeutics (MNPR)
CIK: 0001645469
Period of Report: 2023-02-01

Reporting Person: KLAUSNER ARTHUR J (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2023-02-01	Stock Options	$3.16	A	13930	Acquired	2033-02-01	Common Stock (13930)	Direct
2023-02-01	Restricted Stock Units	$0	A	10133	Acquired		Common Stock (10133)	Direct

Footnotes

F1: Options vest 25% quarterly on March 31, 2023, June 30, 2023, September 30, 2023 and December 31, 2023.

F2: RSUs vest 25% quarterly on March 31, 2023, June 30, 2023, September 30, 2023 and December 31, 2023.